Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.

Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.

Kong AN, Tomasko L, Waldman SA, Osborne B, Deutsch PJ, Goldberg MR, Bjornsson TD.

J Clin Pharmacol. 1995 Oct;35(10):1008-15.

PMID:
8568008
2.

Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers.

De Smet M, Schoors DF, De Meyer G, Verbesselt R, Goldberg MR, Fitzpatrick V, Somers G.

Br J Clin Pharmacol. 1995 Dec;40(6):571-5.

3.

Absence of an effect of levofloxacin on warfarin pharmacokinetics and anticoagulation in male volunteers.

Liao S, Palmer M, Fowler C, Nayak RK.

J Clin Pharmacol. 1996 Nov;36(11):1072-7.

PMID:
8973996
4.

Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ.

J Clin Pharmacol. 1999 May;39(5):495-500.

PMID:
10234597
6.

Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension.

Sasaki M, Fujimura A, Harada K, Sunaga K, Ebihara A.

J Clin Pharmacol. 1996 May;36(5):403-8.

PMID:
8739018
7.

Norfloxacin does not alter warfarin's disposition or anticoagulant effect.

Rocci ML Jr, Vlasses PH, Distlerath LM, Gregg MH, Wheeler SC, Zing W, Bjornsson TD.

J Clin Pharmacol. 1990 Aug;30(8):728-32.

PMID:
2401751
8.

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, Lens S, Porras AG, Dieck J, Keymeulen B, Gertz BJ.

Clin Pharmacol Ther. 2000 Dec;68(6):626-36.

PMID:
11180023
9.

Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin.

Mangold B, Gielsdorf W, Marino MR.

Eur J Clin Pharmacol. 1999 Oct;55(8):593-8.

PMID:
10541778
10.
11.

Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.

Schall R, Müller FO, Hundt HK, Duursema L, Groenewoud G, Middle MV.

Arzneimittelforschung. 1996 Jan;46(1):41-6.

PMID:
8821516
12.

Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.

Ragueneau-Majlessi I, Levy RH, Meyerhoff C.

Epilepsy Res. 2001 Nov;47(1-2):55-63.

PMID:
11673021
13.

No pharmacokinetic or pharmacodynamic interaction between rivastatin and warfarin.

Schall R, Müller FO, Hundt HK, Ritter W, Duursema L, Groenewoud G, Middle MV.

J Clin Pharmacol. 1995 Mar;35(3):306-13.

PMID:
7608323
14.

The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.

Gu N, Kim BH, Lim KS, Kim SE, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.

Clin Ther. 2012 Jul;34(7):1592-600. doi: 10.1016/j.clinthera.2012.06.004. Epub 2012 Jun 22.

PMID:
22727611
15.
16.

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.

Mallikaarjun S, Bramer SL.

Clin Pharmacokinet. 1999;37 Suppl 2:79-86.

PMID:
10702890
17.

Divergent effects of raloxifene HCI on the pharmacokinetics and pharmacodynamics of warfarin.

Miller JW, Skerjanec A, Knadler MP, Ghosh A, Allerheiligen SR.

Pharm Res. 2001 Jul;18(7):1024-8.

PMID:
11496940
18.

The pharmacokinetics and pharmacodynamics of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) in the dog.

Christ DD, Wong PC, Wong YN, Hart SD, Quon CY, Lam GN.

J Pharmacol Exp Ther. 1994 Mar;268(3):1199-205.

PMID:
8138932

Supplemental Content

Support Center